Neurocrine Biosciences vs BIO-TECHNE (NBIX vs TECH)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Neurocrine Biosciences is the larger company by revenue ($2.9B vs $1.2B) and market value ($17.3B vs $11.1B). Neurocrine Biosciences has grown revenue faster over the last 4 fiscal years (+152.4% cumulative vs +31.0%). Neurocrine Biosciences runs the higher operating margin (21.6% vs 8.4%). Neurocrine Biosciences trades at the lower trailing P/E (26.8x vs 101.9x).
About Neurocrine Biosciences
Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. Its main products include FDA-approved drugs such as INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY for classic congenital adrenal hyperplasia. The company serves patients in the United States and select international markets through specialty pharmacy networks and a specialized sales force.
About BIO-TECHNE
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments: Protein Sciences, which provides biological reagents and protein analysis tools for research and therapeutic development, and Diagnostics and Spatial Biology, which offers diagnostic assays, spatial biology solutions, and molecular diagnostic products. Bio-Techne serves customers including academic researchers, pharmaceutical and biotech companies, and clinical diagnostic laboratories.
Head to head (NBIX FY2025 vs TECH FY2025)
| Metric | NBIXFY2025 | TECHFY2025 |
|---|---|---|
| Revenue | $2.86B | $1.22B |
| Revenue growth (YoY) | 21.4% | 5.2% |
| Gross margin | — | 64.8% |
| Operating margin | 21.6% | 8.4% |
| Net margin | 16.7% | 6.0% |
| Net income | $478.6M | $73.4M |
| Diluted EPS | $4.67 | $0.46 |
| FCF margin | 26.2% | 21.0% |
| ROE | 14.7% | 3.8% |
| Debt / equity | — | 0.2× |
| Market cap | $17.30B | $11.11B |
| P/E (TTM) | 26.8× | 101.9× |
Fundamentals are from each company’s SEC filings (NBIX FY2025, TECH FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| NBIX | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| TECH | $931.0M | $1.11B | $1.14B | $1.16B | $1.22B |
Peer standing
Where each company ranks among the 71 biotech companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | NBIX | TECH |
|---|---|---|
| Operating margin | 21.6%63rd percentile of 31 | 8.4%57th percentile of 31 |
| Net margin | 16.7%61st percentile of 32 | 6.0%45th percentile of 32 |
| FCF margin | 26.2%78th percentile of 28 | 21.0%67th percentile of 28 |
| Revenue growth (YoY) | +21.4%54th percentile of 64 | +5.2%35th percentile of 64 |
| ROE | 14.7%80th percentile of 61 | 3.8%73rd percentile of 61 |
| P/E (TTM) | 26.8×75th percentile of 21 | 101.9×90th percentile of 21 |
| Short interest (days to cover) | 4.20d46th percentile of 71 | 1.47d10th percentile of 71 |
Short interest
| FINRA settlement data | NBIX | TECH |
|---|---|---|
| Shares sold short | 5.5M | 15.9M |
| Change vs prior settlement | -2.8% | -12.6% |
| Days to cover | 4.20 | 1.47 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | NBIX | TECH |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 26 ($62.2M) | 1 ($320,386) |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
5 tracked 13F managers hold both Neurocrine Biosciences and BIO-TECHNE as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, Gotham Asset Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
AMGN vs NBIXBIIB vs NBIXEXEL vs NBIXGILD vs NBIXMRNA vs NBIXNBIX vs RVMDAll biotech stocks →All comparisons →
Track NBIX and TECH
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.